Can We Talk: Strategies to Communicate Long-Acting Injectables (LAIs) as an Effective Treatment Option for Bipolar I Disorder

Launch Date

11/19/2020

Credit Amount

0.00 Expired

Credit Expires

11/19/2022

Faculty

Roger S. McIntyre, MD, FRCPC

University of Toronto, University Health Network, Toronto, ON

Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA), Chicago, IL

Clinical Professor, Department of Psychiatry and Neurosciences, University of California School of Medicine, Riverside, CA

Roger S. McIntyre, MD, FRCPC

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. He is Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre also serves as Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor at the College of Medicine at Korea University. Additionally, Dr. McIntyre is also Clinical Professor at the State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor in the Department of Psychiatry and Neurosciences at the University of California School of Medicine. Dr. McIntyre was named by Clarivate Analytics as one of “The World’s Most Influential Scientific Minds” from 2014 through 2019. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is also the President and CEO of Champignon.

Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre was the lead author for the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. He has also contributed to the Canadian Network for Mood and Anxiety (CANMAT) guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published more than 600 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

Statement of Need

Bipolar I disorder (BD-I) is an often chronic, debilitating condition in which medication is a mainstay of treatment. However, medication non adherence can negatively impact clinical outcomes, increasing the risk for relapse and (re)hospitalization. Long-acting injectables (LAIs), particularly relative to oral therapies, are an effective treatment option for BD-I that overcomes nonadherence, thereby promoting remission and functional recovery. However, despite their safety and efficacy, both clinician and patient factors impede their use in routine practice.

This CME Outfitters BriefCase utilizes a patient case to guide clinicians on best practices to engage patients in treatment planning for BD-I, including the feasibility of LAIs as an effective treatment option.

Learning Objectives

At the end of this CME/CE activity, participants should be able to incorporate collaborative care discussions with patients with bipolar I disorder that include incorporating LAIs as a potential management option.

The following learning objectives pertain only to those requesting CNE or CPE credit: Describe ways to incorporate collaborative care discussions with patients with bipolar I disorder that include incorporating LAIs as a potential management option.

Financial Support

Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Target Audience

Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

UAN: JA0007185-0000-21-152-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. McIntyre reports that he receives grants/research support from The Canadian Institutes of Health Research (CIHR); Global Alliance for Chronic Diseases (GACD); National Natural Research Foundation of China; and Stanley Medical Research Institute. He is a consultant/on the speakers bureau for Allergan; Intra-Cellular Therapies INc.; Janssen Pharmaceutical, Inc.; Lundbeck Canada Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka Canada Pharmaceutical Inc.; Pfizer Inc.; Purdue Pharma Canada; Sunovion Pharmaceuticals Canada Inc.; and Takeda Pharmaceutical Company Limited.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.